CLOV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clover Health Investments Corp (CLOV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown significant YoY revenue growth and improvement in net income, the stock's technical indicators suggest it is overbought, and insider selling has surged significantly. Additionally, there are no strong trading signals or recent positive news catalysts to support immediate entry.
The MACD histogram is positive at 0.0509 and expanding, indicating bullish momentum. However, the RSI is at 88.33, signaling the stock is overbought. Moving averages are converging, and the stock is trading near its resistance level of 2.162, suggesting limited short-term upside.
Analysts see favorable 2026 rates from CMS and a 4-star plan as potential tailwinds.
Insider selling has increased by 2175.53% over the last month, indicating potential lack of confidence from insiders. Analysts have recently lowered price targets, and there is no recent news or significant hedge fund activity to support a bullish case.
In Q3 2025, revenue increased to $496.65M (+50.05% YoY), net income improved to -$24.38M (+166.27% YoY), and EPS rose to -0.05 (+150% YoY). Gross margin remained stable at 100%.
Canaccord maintains a Buy rating but lowered the price target to $3.20 from $3.70, citing strong tailwinds for 2026. UBS maintains a Neutral rating and lowered the price target to $2.75 from $3. Analysts are cautiously optimistic but have tempered expectations.
